COMMUNIQUÉS West-GlobeNewswire

Aptose Biosciences Doses First Patient in Re-Initiation of Phase 1b Clinical Study of APTO-253 in Relapsed or Refractory Hematological Malignancies
26/11/2018
SAN DIEGO and TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (NASDAQ: APTO, TSX: APS), a clinical-stage company developing highly differentiated therapeutics targeting the underlying mechanisms of [...]
Resonant Inc. Initiates $4 Million Stock Repurchase Program
26/11/2018
GOLETA, Calif., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Resonant Inc. (NASDAQ: RESN), a leader in transforming the way radio frequency, or RF, front-ends are being designed and delivered for wireless devices, announced its [...]
Form 8 (DD) - Shire plc
26/11/2018
FORM 8 (DD) PUBLIC DEALING DISCLOSURE BY A PARTY TO AN OFFER OR PERSON ACTING IN CONCERT (INCLUDING DEALINGS FOR THE ACCOUNT OF DISCRETIONARY INVESTMENT CLIENTS) Rules 8.1, 8.2 and 8.4 of the Takeover Code (the “Code”) [...]
Athenex Announces Initiation of a Phase I/II Clinical Study of Oraxol in Combination with Anti-PD1
26/11/2018
BUFFALO, N.Y., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Athenex, Inc. (NASDAQ:ATNX), a global biopharmaceutical company dedicated to the discovery, development and commercialization of novel therapies for the treatment of [...]
Repeat: Canopy Rivers Secures International Joint Venture Rights and Accelerates Development at PharmHouse
26/11/2018
NOT FOR DISSEMINATION IN THE UNITED STATES OR THROUGH U.S. NEWSWIRES TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Canopy Rivers Inc. (“ Canopy Rivers ” or the “ Company ”) (TSXV: RIV) is pleased to announce it has, [...]
Zafgen Provides Update on Investigational New Drug Application for ZGN-1061
26/11/2018
BOSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Zafgen, Inc. (Nasdaq:ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients [...]
Aleafia Posts Record Revenue in Q3 2018, 36% Increase Over Previous Quarter
26/11/2018
First Quarter of Profitability for Clinic and Cannabis Product Divisions 99% of 98,000 kg Annual Cannabis Production Capacity to Come Online in 2019 TORONTO, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aleafia Health Inc. (TSXV: [...]
GW Pharmaceuticals Announces Second Positive Phase 3 Pivotal Trial for EPIDIOLEX® (cannabidiol) oral solution CV in Patients with Dravet Syndrome
26/11/2018
- Primary endpoint achieved with both EPIDIOLEX doses compared to placebo - - Today’s data represents the fourth positive Phase 3 pivotal trial for EPIDIOLEX in Dravet syndrome and Lennox-Gastaut Syndrome - - EPIDIOLEX [...]
Aravive Announces Participation at Upcoming Investor Conference
26/11/2018
HOUSTON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Aravive, Inc. (Nasdaq: ARAV), a clinical-stage biopharmaceutical company, today announced that company management will participate at the following upcoming investor conference [...]
Edge Therapeutics Enters into Merger Agreement with PDS Biotechnology to Form Clinical-Stage Cancer Immunotherapy Company
26/11/2018
-Merger would create publicly-traded immuno-oncology biotechnology company developing novel products for treating early- and late-stage cancer- -Growing product pipeline utilizing Versamune ® , a novel, versatile, multi [...]
Tasly and Mesoblast Initiate Development and Regulatory Activities for MPC-150-IM Heart Failure Cell Therapy in China
26/11/2018
NEW YORK and MELBOURNE, Australia, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Tasly Pharmaceutical Group and Mesoblast Limited (Nasdaq:MESO; ASX:MSB) today announced that the first Joint Steering Committee (JSC) meeting for [...]
Innovate Biopharmaceuticals Strengthens Clinical Development with the Addition of Patrick H. Griffin, M.D., F.A.C.P.
26/11/2018
RALEIGH, N.C., Nov. 26, 2018 (GLOBE NEWSWIRE) -- Innovate Biopharmaceuticals, Inc . (Nasdaq: INNT), a clinical-stage biotechnology company focused on developing novel medicines for autoimmune and inflammatory diseases, [...]
Transactions under Novozymes’ stock buyback program
26/11/2018
Please read the full announcement in the attached PDF Attachment 2018_65_Stock_Buybackprogram_EN
Registration of the reduced quantity of shares in Nexstim Plc (the first phase)
26/11/2018
Company announcement, Helsinki, 26 November 2018 at 10:00 Registration of the reduced quantity of shares in Nexstim Plc (the first phase) The Extraordinary General Meeting of Nexstim Plc (NXTMH:HEX, NXTMS:STO), the [...]
Latvijas Juras medicinas centrs JSC: interim report for the 9 months of 2018
26/11/2018
Latvijas Juras medicinas centrs JSC: interim report for the 9 months of 2018, approved by the Board at 21.11.2018. Member of the Board: Juris Imaks, phone: 29512492
JSC Olainfarm Invites To Join Company’s Presentation At CEO Meets Investors Event In Riga
26/11/2018
JSC Olainfarm is inviting investors to join Olainfarm’s online presentation today at 11:45 (EET) at the annual CEO Meets Investor event in Riga. The presentation will be led by the Advisor to the Board of JSC Olainfarm [...]
Chi-Med Announces First Commercial Launch of Fruquintinib Capsules (Elunate®)
26/11/2018
LONDON, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Hutchison China MediTech Limited (“Chi-Med”) (AIM/Nasdaq: HCM) today announces the first commercial launch of fruquintinib capsules (Elunate ® ) with the initiation of product [...]
Telix Pharmaceuticals Acquires Advanced Nuclear Medicine Ingredients (ANMI) SA
26/11/2018
MELBOURNE, Australia, BRUSSELS and LIÈGE, Belgium, Nov. 26, 2018 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX:TLX) (“Telix”, the “Company”), a clinical-stage biopharmaceutical company focused on the [...]
MDxHealth (R): MDxHealth Announces Approval for SelectMDx for Prostate Cancer by New York State
26/11/2018
NEWS RELEASE REGULATED INFORMATION IRVINE, CA, and HERSTAL, BELGIUM - 07.00 CET, 26 November 2018 - MDxHealth SA (Euronext: MDXH.BR) today announces that the New York State Department of Health has approved its [...]

Pages